Do you prefer assessing cystatin C or creatinine when monitoring a patient’s eGFR who is receiving chemotherapy for malignancy?

If the patient is on a drug known to interfere with creatinine handling in the renal tubules (e.g. abemaciclib), then I will intermittently check the cystatin C to differentiate true AKI from pseudo-hypercreatinemia since these drugs can also cause true AKI.